A study by Martimer et al. aimed to determine if 18F-FDG and FES can detect hormone-induced changes in tumor metabolism and ER levels before and after tamoxifen treatment, and if these PET findings could predict hormonally responsive breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.